Tango Therapeutics (TNGX) News Today

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) major shareholder Rock Ventures Iv L.P. Third sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $9.82, for a total value of $1,964,000.00. Following the sale, the insider now owns 17,872,074 shares of the company's stock, valued at approximately $175,503,766.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 4.9%

Tango Therapeutics (NASDAQ:TNGX) Trading Up 5.1%

Tango Therapeutics (NASDAQ:TNGX) Trading Down 7%

Wellington Management Group LLP grew its holdings in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 110.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 170,228 shares of the company's

Fisher Asset Management LLC acquired a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 100,691 shares of the company's s

Mass General Brigham Inc acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 354,192 shares of the company's stock, valued at approximat

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been given a consensus rating of "Buy" by the seven ratings firms that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the

Perceptive Advisors LLC lowered its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 54.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,111,870 shares of the company's stock after selling 1,307,098 shares during the period. Per

Boxer Capital LLC lifted its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 15.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,198,642 shares of the company's stock after acquiring

RTW Investments LP purchased a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,966,752 shares of the company's stock, valued at approximately $19,

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Mva Investors, Llc sold 63,000 shares of the firm's stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $7.24, for a total transaction of $456,120.00. Following the completion of the transaction, the insider now directly owns 420,524 shares in the company, valued at $3,044,593.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Tango Therapeutics (NASDAQ:TNGX) Shares Up 6.8%

HC Wainwright reduced their price target on Tango Therapeutics from $16.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Wedbush increased their Q2 2024 EPS estimates for Tango Therapeutics in a research report issued on Thursday, May 23rd. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.29) per share for the qua

Guggenheim decreased their price objective on shares of Tango Therapeutics from $16.00 to $14.00 and set a "buy" rating for the company in a report on Friday.

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among

Tango Therapeutics (NASDAQ:TNGX) Shares Gap Down Following Analyst Downgrade

Tango Therapeutics (NASDAQ:TNGX) Trading Down 3.7%

Tango Therapeutics (NASDAQ:TNGX) Shares Down 7.3%

Fisher Asset Management LLC purchased a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 100,691 shares of the company's stock, valued at approxim

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $7.61, for a total transaction of $456,600.00. Following the sale, the insider now owns 483,524 shares in the company, valued at approximately $3,679,617.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 7%

Tango Therapeutics (NASDAQ:TNGX) Shares Down 3.8%

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Investment analysts at B. Riley issued their Q2 2024 earnings per share (EPS) estimates for shares of Tango Therapeutics in a report issued on Monday, April 15th. B. Riley analyst Y. Zhi expects that the company will earn ($0.34) per share fo

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Investment analysts at B. Riley issued their Q1 2024 earnings estimates for Tango Therapeutics in a report issued on Monday, April 15th. B. Riley analyst Y. Zhi forecasts that the company will post earnings of ($0.33) per share for the quarte

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Cantor Fitzgerald issued their FY2024 earnings per share estimates for Tango Therapeutics in a research note issued on Tuesday, April 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.28) per share f

Vanguard Group Inc. lifted its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 7.2% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 2,939,843 shares of the company's stock after acquiring an additional 197,624 shares during t

Tango Therapeutics (NASDAQ:TNGX) Trading Down 3.3%

Tango Therapeutics (NASDAQ:TNGX) Trading Up 5.2%

Cantor Fitzgerald initiated coverage on Tango Therapeutics in a research note on Thursday. They issued an "overweight" rating for the company.